Ishira

[Seminars in Cancer Biology] The authors summarize the evolution of mutation-based molecular subtyping of SCLC, as well as the trends in molecular targeting and immunotherapeutic for SCLC.

[International Journal of Cancer] Scientists summarize the tumor-promoting role and molecular mechanisms of cancer-associated fibroblasts in NSCLC, including their origin, phenotypic changes and heterogeneity, and their functional roles in carcinogenesis.

[International Journal of Clinical Oncology] Myosteatosis might serve as an independent indicator of unfavorable survival outcomes for overall survival and progression-free survival in lung cancer patients.

[Avalo Therapeutics, Inc.] Avalo Therapeutics, Inc. announced that the first patient has been dosed in the company’s Phase II PEAK trial evaluating AVTX-002 for the treatment of NEA.

[EpiEndo Pharmaceuticals (B3CNewswire, Inc.)] EpiEndo Pharmaceuticals, the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human study with EP395 in healthy subjects.

[Clinical Cancer Research] Researchers evaluated if the cell surface protein CDCP1 could be exploited to treat metastatic CRPC with radioligand therapy, including in PSMA low subsets.